Stocks

Magazine articles on individual stocks, valuation, accounting standards, IPO's, brokerages, exchanges.

Old Articles: <Older 6601-6610 Newer>

The Motley Fool March 31, 2005 Tom Taulli	Limited Resources? Sarbanes-Oxley has been a boon for Resources Connection, an area the professional services firm specializes in. But things seem to be slowing down. Investors, take note.
The Motley Fool March 31, 2005 Tim Beyers	SpaceDev Revs Up The upstart space exploration firm delivers Rule Breaking sales gains. Still, investing, like space travel, is entirely about risk.
The Motley Fool March 31, 2005 Stephen D. Simpson	The DOJ Goes Fishing for Orthopedics The government's industry-wide investigation of orthopedics is more of a buying opportunity than a real threat.
The Motley Fool March 31, 2005 Nathan Slaughter	Hurry In to Hastings The multimedia retailer is looking even cheaper after reporting a sharp fourth-quarter earnings drop.
The Motley Fool March 31, 2005 Tim Beyers	Stock Madness 2005: Buffalo Wild Wings vs. PetroKazakhstan Two investors go head-to-head over which is the best bet on the Street in "Stock Madness 2005," a contest based loosely on the annual NCAA College Basketball Tournament, a.k.a. March Madness.
The Motley Fool March 31, 2005 Nathan Parmelee	Was Odimo's IPO Too Early? The high-end retailer's fourth-quarter earnings show the company continues to lose money.
The Motley Fool March 31, 2005 Rich Duprey	Hooker Furniture Gets Scratched Furniture maker misses estimates on weak domestic sales and flat future. But there may yet be opportunities to get Hooker at even better prices.
The Motley Fool March 31, 2005 Stephen D. Simpson	Another "No" for Lexapro This latest FDA setback shouldn't hurt Forest Labs much, and the shares look like a bargain.
The Motley Fool March 31, 2005 Beirne White	Lessons From Great "Mentor" Capitalists Visionary moneymakers he's known, met, or seen all tell the author these same two things. Clarity and purpose build bold fortunes. Now apply that to investing.
The Motley Fool March 31, 2005 Stephen D. Simpson	Strike Three for Tysabri A third confirmed case of PML all but eliminates Tysabri's potential as a blockbuster drug. For Elan and Biogen investors, the news continues to sting.
<Older 6601-6610 Newer> Return to current articles.